Fund moves
100 tracked managers disclosed the same change for Q3 2025. From a 13F filed Dec 1, 2025 covering holdings at Sep 30, 2025 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 5, 2025 · Filed Nov 6, 2025
A major shareholder of Eli Lilly sold $5.97M of Eli Lilly shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$5,972,570
Shares × reported transaction price
6 days after results of Oct 30, 2025, 91 days before results of Feb 4, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $925.81 on Nov 5, 2025, within 1% of its 52-week high, after a 25% rise over the previous 30 trading days
52-week range $625.65 (Aug 8, 2025) to $929.72 (Mar 3, 2025), 99% of the way up, from 250 adjusted closes. 30 trading days earlier: $741.85 on Sep 24, 2025. Describes the past only, not a forecast
RSI 77, 17% above its 200-day average, 17% above its 50-day average, 0% below the 52-week high, 20-day volatility 29% a year, against the S&P 500: +8 points over 1 month, +37 points over 3 months, −2 points over 6 months
From the adjusted closes up to Nov 5, 2025. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
Traded 13 days before LLY filed an 8-K: changed a top executive or board member (Nov 18, 2025)
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
FDA approved Retevmo on Nov 20, 2025, 15 days after this trade.
New use approved (efficacy supplement). Active ingredient: Selpercatinib. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +10.9% | +0.1% | +10.8% |
| 30 days | +7.9% | +1.9% | +6.0% |
| 90 days | +10.4% | +1.0% | +9.4% |
| 180 days | +6.8% | +9.4% | −2.6% |
| 365 days | +52.8% | +12.2% | +40.6% |
Past results only. Not a forecast.
Fund moves
100 tracked managers disclosed the same change for Q3 2025. From a 13F filed Dec 1, 2025 covering holdings at Sep 30, 2025 — a quarter-end snapshot, not a live trade.
Insider selling
Traded Nov 25, 2025 · filed 1 day laterNot reported under a pre-arranged trading plan
A major shareholder of Eli Lilly sold $862K of Eli Lilly shares. The filing does not indicate a pre-arranged trading plan.
Insider selling
Traded Nov 25, 2025 · filed 1 day laterNot reported under a pre-arranged trading plan
A major shareholder of Eli Lilly sold $1.36M of Eli Lilly shares. The filing does not indicate a pre-arranged trading plan.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.